STYLAGE® XXL BI-FLEX® with Mepivacaine

Description

Name: STYLAGE® XXL BI-FLEX® with Mepivacaine
Manufacturer: Vivacy
Active Substance(s): CROSS-LINKED HYALURONIC ACID (HA), MANNITOL, MEPIVACAINE
Strength: 21mg/g HA, 3mg/ml Mephivacaine Hydrochloride
Package Content: 2 x 1ml Pre-Filled Syringes, 2 x 25G40mm + 2 x 27G½, 1 x 23G½ Needles

STYLAGE® XXL BI-FLEX® with Mepivacaine is the successor to STYLAGE® XXL (Bi-SOFT®), developed by Laboratories VIVACY, France, for patients with extreme volume loss who require maximum-depth structural facial volumization. Formulated with 21mg/g cross-linked hyaluronic acid and 3mg/mL mepivacaine hydrochloride, it is the deepest-plane formulation in the STYLAGE® range, indicated for severe-to-extreme facial volume deficit when STYLAGE® XL is insufficient. The updated BI-FLEX® syringe platform offers improved ergonomics, injection precision, and safety, while the new deep green and white packaging distinguishes it from previous generations. Practitioners seeking to buy STYLAGE® XXL BI-FLEX® with Mepivacaine online may contact Maylips support team for guidance.

• Strength: 21mg/g HA | 3mg/mL Mepivacaine Hydrochloride
• Active Ingredient: Hyaluronic acid (cross-linked) 21mg/g; Mepivacaine Hydrochloride 3mg/mL
• Dosage Form: Injectable gel — 2 × 1mL prefilled syringes + 2 × 25G 40mm needles + 2 × 27G ½” needles + 1 x 23G½ Needles
• FDA Approval Date: STYLAGE® is NOT FDA-approved for U.S. use. The product carries CE marking for European Union markets only (CE certification for medical devices under the EU MDR).
• Molecular Type: Cross-linked hyaluronic acid (IPN-Like Technology™) with mepivacaine hydrochloride
• Intended Use: Extreme volume loss, maximum-depth facial volumization, and structural contouring — for experienced licensed aesthetic professionals
• Brand: STYLAGE®
• Country of Origin: France
• Manufacturer: Laboratories VIVACY (Paris, France)

STYLAGE® XXL BI-FLEX® with Mepivacaine is the deepest-plane filler in the STYLAGE® portfolio. It is engineered specifically for patients with severe-to-extreme facial volume loss who require maximum structural support at the supraperiosteal level. It is typically selected when STYLAGE® XL or lighter formulations cannot deliver sufficient correction.

Its primary treatment areas are:

• Cheeks and midface (structural restoration)
• Cheekbones (augmentation)
• Chin and jawline (projection and contouring)

Core Technologies & Upgrades

• IPN-Like Technology™: Creates two interlocked hyaluronic acid polymer networks. This design enhances gel cohesivity and structural resilience, allowing the filler to maintain strict projection under significant mechanical stress at deep facial planes.
• BI-FLEX® Syringe Platform: Replaces the former Bi-SOFT® system. This updated delivery platform offers improved ergonomics, superior injection precision, and enhanced practitioner control.

The Mepivacaine Distinction

A defining feature of this formulation is the integration of mepivacaine hydrochloride (3mg/mL) instead of traditional lidocaine. This amide-type local anesthetic provides distinct clinical advantages for deep structural work:

• Faster Tissue Onset & Neutral pH: Enhances immediate patient comfort during deep delivery.
• No Vasoconstrictor Component: Unlike lidocaine, which acts as a vasodilator, mepivacaine minimizes blood vessel dilation. This property is highly desirable in deep subcutaneous and supraperiosteal planes to potentially reduce post-procedure bruising and erythema.
• Shorter Half-Life: Allows practitioners to safely evaluate true treatment outcomes sooner during the immediate post-procedure period.

For practitioners evaluating whether STYLAGE® is a good filler, the combination of a maximum-depth indication, IPN-Like Technology™, the ergonomic BI-FLEX® delivery system, and CE-marked manufacturing positions it as a premier option.

STYLAGE® products are CE-marked for European markets; regulatory status in the United States (not FDA approved) and other jurisdictions must be independently verified.

STYLAGE® XXL BI-FLEX® with Mepivacaine is intended for experienced aesthetic medicine professionals treating patients with severe-to-extreme facial volume loss. The STYLAGE® XXL BI-FLEX® with Mepivacaine injection is specifically designed for maximum-depth structural volumization and should only be administered by qualified practitioners with expertise in supraperiosteal injection techniques.

Common indications include:

• Extreme facial volume loss affecting the cheeks, temples, and midface
• Structural cheekbone augmentation
• Chin projection and profile balancing
• Jawline definition and contour enhancement
• Deep correction of nasolabial folds and marionette lines when a significant volume component is present

When selecting candidates for treatment, practitioners should assess the severity of volume loss, treatment area, condition of the patient’s skin, skin type, facial anatomy, and overall treatment goals. Because STYLAGE® XXL is intended for deep structural correction, supraperiosteal injection expertise is essential for achieving safe and predictable outcomes.

Practitioners comparing injectable dermal fillers should evaluate intended depth and volumizing capacity to confirm the formulation aligns with the treatment indication before sourcing.

STYLAGE® XXL BI-FLEX® with Mepivacaine restores facial volume through cross-linked hyaluronic acid placed at deep tissue planes. Once injected, the gel binds water molecules and provides immediate volumizing support while helping maintain facial structure in areas affected by aging, fat loss, or skeletal changes.

IPN-Like Technology™ enhances the gel’s resistance to deformation under sustained mechanical load. This characteristic is particularly important in deep facial planes where fillers must maintain projection and structural support over time.

For practitioners asking how long STYLAGE® filler lasts, duration varies according to factors such as skin type, treatment area, metabolism, lifestyle, and injection technique; practitioners should consult the current IFU for product-specific duration data.

• Target Planes: Deep subcutaneous or supraperiosteal levels.
• Delivery Hardware: Administered using the included 25G 40mm needle.
• Method: Bolus or fanning techniques. Aspiration is highly recommended prior to product delivery to minimize intravascular risk.
• Patient Comfort: The co-formulated mepivacaine hydrochloride (3mg/mL) significantly reduces pain during deep-plane delivery. Additional regional nerve block anesthesia may be used at the practitioner’s discretion.
• Post-Treatment Care: Patients must avoid excessive sun exposure, UV light, and extreme heat until initial redness and swelling completely resolve.

Side Effect Profile

These local reactions are temporary, typical for deep volumizing procedures, and generally resolve within a few days (though recovery depends on the specific treatment area and skin type):

• Redness and swelling (Note: Deep-plane swelling may persist longer than with superficial fillers)
• Tenderness and mild discomfort
• Bruising at the injection site

While rare, severe complications can occur if the filler enters a blood vessel or triggers an allergic reaction. Practitioners must be prepared to manage:

• Vascular occlusion
• Skin necrosis
• Visual disturbances (iatrogenic blindness)

Clinical Safety Screening

• Pre-Treatment Screening: Patients must be thoroughly screened for hypersensitivity to hyaluronic acid or amide-type local anesthetics (including mepivacaine) prior to injection.
• Emergency Readiness: Practitioners must maintain an intimate knowledge of facial vascular anatomy, follow strict safety protocols, and have immediate access to an emergency kit containing hyaluronidase to dissolve the gel if a vascular complication occurs.

Always refer to the complete product Instructions for Use (IFU) for comprehensive safety guidance.

STYLAGE® XXL BI-FLEX® with Mepivacaine is manufactured by Laboratories VIVACY in France and is CE-marked for professional aesthetic use in applicable European markets. The product is not FDA-approved and cannot be marketed for cosmetic use in the United States. Regulatory requirements vary by jurisdiction; practitioners should verify local regulations, approved indications, and compliance requirements before procurement or clinical use. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact Maylips support team for sourcing information and documentation support.

For sourcing guidance, contact Maylips support team.

Regulatory information current as of mid 2026. Practitioners should confirm local regulatory status before sourcing.